文献速递类风湿关节炎

症状出现6周内转诊风湿科与7-12周就诊对早期关节炎长期结局的比较:观察性队列研究

Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study.
PubMed 文献 · Lancet Rheumatol · 2020-04-28

该观察性队列研究纳入Leiden EAC和法国ESPOIR两个队列中确诊类风湿关节炎的患者,比较症状出现后6周内、7-12周及12周后首次就诊风湿科对持续无DMARD缓解和影像学进展的影响。结果显示6周内就诊与更高的持续无DMARD缓解机会相关,但与影像学进展无显著改善关联。

要点

  • 症状出现6周内就诊风湿科与更高的持续无DMARD缓解率相关。
  • 6周内就诊与7-12周就诊相比,影像学进展无显著差异。
  • 6周内就诊与12周后就诊相比,影像学进展更少(meta分析β=0·95)。

核心结论

  • 症状出现6周内就诊风湿科对实现持续无DMARD缓解有益,但对影像学进展无获益。

研究设计与样本

  • 观察性队列研究,纳入Leiden EAC队列1996年1月1日至2017年12月31日的1025例类风湿关节炎患者和ESPOIR队列2002年11月1日至2005年4月30日的514例类风湿关节炎患者。
  • 按症状出现至首次风湿科就诊时间分为6周内、7-12周和12周后三组,主要结局为持续无DMARD缓解和影像学进展,采用多变量Cox回归、线性混合模型和meta分析。

主要发现

  • EAC队列随访7年时,6周内组127例中30例(24%)、7-12周组223例中45例(20%)、12周后组675例中100例(15%)实现持续无DMARD缓解。
  • ESPOIR队列随访10年时,6周内组11例中3例(27%)、7-12周组100例中11例(11%)、12周后组403例中41例(10%)实现持续无DMARD缓解。
  • EAC多变量分析中,6周内就诊者较7-12周就诊者更常实现持续无DMARD缓解(HR 1·59 [95% CI 1·02-2·49],p=0·042),也优于12周后就诊者(HR 1·54 [95% CI 1·04-2·29],p=0·032)。
  • ESPOIR多变量分析中效应相似但无统计学显著性(6周内 vs 7-12周:HR 2·81 [95% CI 0·75-10·53],p=0·12;6周内 vs 12周后:HR 3·05 [95% CI 0·89-10·49],p=0·077)。
  • 两队列meta分析显示,6周内就诊较7-12周就诊(HR 1·69 [95% CI 1·10-2·57],p=0·016)和12周后就诊(HR 1·67 [95% CI 1·08-2·58],p=0·020)与更高的持续无DMARD缓解机会相关。

临床怎么用

  • 对疑似早期关节炎患者,应尽量在症状出现6周内转诊至风湿免疫科,以争取更高的持续无DMARD缓解机会。
  • 6周内就诊的获益主要体现在缓解率而非影像学进展,临床决策需综合评估。

局限性

  • 为观察性队列研究,可能存在未测量混杂因素。
  • ESPOIR队列中6周内就诊组样本量较小(11例),相关效应估计不精确且无统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first recommendation of the European League Against Rheumatism for the management of early arthritis states that patients should be referred to, and seen by, a rheumatologist within 6 weeks after symptom onset. However, implementation of this recommendation is a challenge, and evidence supporting this timeframe compared with longer timeframes is absent. Therefore, we aimed to investigate whether visiting a rheumatologist within 6 weeks of symptom onset relates to improved long-term outcomes compared with visiting a rheumatologist between 7 and 12 weeks after symptom onset. METHODS: In this observation cohort study, consecutive patients with rheumatoid arthritis from the Leiden Early Arthritis Clinic (EAC) and the French Etude et Suivi des Polyarthrites Indifferenciées Recentes (ESPOIR) were included. In this analysis, we included patients who were diagnosed with rheumatoid arthritis and classified according to 1987 American College of Rheumatology criteria, and with symptom onset and remission data available. Patients were categorised into groups based on time between symptom onset and first encounter with a rheumatologist: within 6 weeks, between 7 weeks and 12 weeks, and after 12 weeks. The main outcomes were sustained disease-modifying antirheumatic drug (DMARD)-free remission and radiographic progression. Multivariable Cox regression, linear mixed models, and meta-analyses were used. FINDINGS: 1025 patients with rheumatoid arthritis included in the EAC between Jan 1, 1996, and Dec 31, 2017, and 514 patients with rheumatoid arthritis included in ESPOIR between Nov 1, 2002, and April 30, 2005, were included in this analysis. Median follow-up was 7·1 years (IQR 3·9-12·2) in the EAC and 10·0 years (9·0-10·0) in ESPOIR. After 7 years of follow-up in the EAC, 30 (24%) of 127 patients with a time to encounter of 6 weeks or less, 45 (20%) of 223 patients with a time of 7-12 weeks, and 100 (15%) of 675 patients with a time of more than 12 weeks achieved sustained DMARD-free remission. After 10 years of follow-up in ESPOIR, three (27%) of 11 patients with a time to encounter of 6 weeks or less, 11 (11%) of 100 patients with a time of 7-12 weeks, and 41 (10%) of 403 patients with a time of more than 12 weeks had sustained DMARD-free remission. In the EAC multivariable analysis, patients who encountered a rheumatologist within 6 weeks obtained sustained DMARD-free remission more often than those seen between 7 and 12 weeks (hazard ratio [HR] 1·59 [95% CI 1·02-2·49], p=0·042), and after 12 weeks (1·54 [1·04-2·29], p=0·032). In the ESPOIR multivariable analysis, similar but non-significant effects were observed (HR 2·81 [95% CI 0·75-10·53], p=0·12, for within 6 weeks vs 7-12 weeks and 3·05 [0·89-10·49], p=0·077, for within 6 weeks vs more than 12 weeks). The meta-analysis of both cohorts showed that the time to encounter of 6 weeks or less was associated with a higher chance of achieving sustained DMARD-free remission than a time of 7-12 weeks (HR 1·69 [95% CI 1·10-2·57], p=0·016) and a time of more than 12 weeks (1·67 [1·08-2·58], p=0·020). The multivariable analysis showed that patients who encountered a rheumatologist within 6 weeks had similar radiographic progression to those seen between 7 and 12 weeks in both cohorts (β=1·00 [95% CI 0·95-1·05], p=0·96, in the EAC and 0·93 [0·80-1·07], p=0·30, in ESPOIR) and to those seen after 12 weeks (β=0·96 [95% CI 0·92-1·00], p=0·064, in the EAC and 0·89 [0·77-1·02], p=0·10, in ESPOIR). In the meta-analysis, a time to encounter of 6 weeks or less was not associated with less radiographic progression than a time of 7-12 weeks (β=0·99 [95% CI 0·95-1·04], p=0·75) but was associated with less radiographic progression than a time of more than 12 weeks (0·95 [0·91-0·99], p=0·028). INTERPRETATION: Visiting a rheumatologist within 6 weeks of symptom onset had benefits for achieving sustained DMARD-free remission, but not for radiographic progression. FUNDING: European Research Council, Dutch Arthritis Society, Merck Sharp & Dohme, INSERM, The French Society of Rheumatology, Pfizer, AbbVie, Lilly, and Sanofi.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Niemantsverdriet E, Dougados M, Combe B, et al. Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study. Lancet Rheumatol. 2020. PMID: 38273596. doi:10.1016/S2665-9913(20)30061-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。